<?xml version="1.0" encoding="UTF-8"?>
<p>Ribavirin (
 <xref ref-type="fig" rid="F3">Figure 3</xref>) is a RdRp inhibitor (
 <xref ref-type="fig" rid="F4">Figure 4</xref>) used to treat various viral infections, for example, infections caused by RSV and hepatitis C virus (HCV) (Ogawa and Morisada, 
 <xref rid="B139" ref-type="bibr">2002</xref>). It was revealed by 
 <italic>in vitro</italic> studies that when ribavirin was administered at a concentration of 50 mg/mL, it showed effective antiviral activity against SARS-CoV (Chan et al., 
 <xref rid="B32" ref-type="bibr">2015</xref>). Unfortunately, this antiviral drug was found to decrease the level of hemoglobin, therefore it can be detrimental for individuals with respiratory distress (Martinez, 
 <xref rid="B124" ref-type="bibr">2020</xref>).
</p>
